| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/26/2006 | EP1682140A2 Methods of use of thrombin receptor antagonists |
| 07/26/2006 | EP1682137A1 Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pain |
| 07/26/2006 | EP1682124A1 Pharmaceutical compositions based on idazoxan salt or one of the polymorphs thereof |
| 07/26/2006 | EP1682103A1 Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation |
| 07/26/2006 | EP1682090A1 Buccal, polar and non-polar spray containing ondansetron |
| 07/26/2006 | EP1682072A2 AChE ANTISENSE DEOXYOLIGONUCLEOTIDE AS AN ANTI-INFLAMMATORY AGENT |
| 07/26/2006 | EP1549649B1 Process for preparing haloalkyl pyrimidines |
| 07/26/2006 | EP1513839B1 3-substituted quinuclidines and their use |
| 07/26/2006 | EP1463830A4 Method for classification of anti-psychotic drugs |
| 07/26/2006 | EP1414447B1 Use of thiazole derivatives for preparing a medicine for protecting mitochondria |
| 07/26/2006 | EP1390543B1 New polynucleotides and polypeptides of the ifnalpha-17 gene |
| 07/26/2006 | EP1381686B1 Inactivation of genes of the mep pathway |
| 07/26/2006 | EP1368299B1 Substituted c-cyclohexylmethylamine derivatives |
| 07/26/2006 | EP1357906B1 Blockade of sodium channels by phenol derivatives |
| 07/26/2006 | EP1313472A4 Method for reducing or eliminating smoking |
| 07/26/2006 | EP1311297B1 A method for reducing stress-induced overproduction of neuropeptide y in an individual |
| 07/26/2006 | EP1263784B1 Novel human ulip/crmp protein and use thereof in diagnosis and treatment of cancers and paraneoplastic neurological syndromes |
| 07/26/2006 | EP1244451B1 Substituted piperazine and piperidine calcium channel blockers |
| 07/26/2006 | EP1240313B1 Homologue enzymes of human heparanase and splice variants thereof |
| 07/26/2006 | EP0929303B1 Cns-penetrant nk-1 receptor antagonists as antidepressant and/or an anti-anxiety agent |
| 07/26/2006 | EP0902003B1 Novel tetralone or benzopyranone derivatives and process for producing the same |
| 07/26/2006 | EP0835136B1 Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate |
| 07/26/2006 | EP0801527B1 Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
| 07/26/2006 | CN1809645A Method for detecting alzheimer's disease |
| 07/26/2006 | CN1809581A Alkylamino alkoxyl substituted C-glycosylisoflavones and preparing method and the use of the same |
| 07/26/2006 | CN1809574A Quinoline 3-amino chroman derivatives |
| 07/26/2006 | CN1809570A [1,2,4 ]triazolo [1,5-a]pyrimidin-2-ylurea derivative and use thereof |
| 07/26/2006 | CN1809565A Pyrrolodihydroisoquinolines as pde10 inhibitors |
| 07/26/2006 | CN1809564A Pyrrolodihydroisoquinolines as PDE10 inhibitors |
| 07/26/2006 | CN1809559A Pyrazole derivatives as phosphodiesterase 4 inhibitors |
| 07/26/2006 | CN1809542A Macrocyclic compounds having aspartic protease inhibiting activity and pharmaceutical uses thereof. |
| 07/26/2006 | CN1809365A Use of adenosine receptor agonists in therapy |
| 07/26/2006 | CN1809361A Use of 2h-[1,3]-oxazino[3,2-a]indole derivatives for the treatment of neuropathic pain |
| 07/26/2006 | CN1809359A Combinations comprising paroxetine and 2-(S)-(4-fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoro-2-methyl-phenyl)-ethyl]-methyl amide for treatment of depression and/or a |
| 07/26/2006 | CN1809356A Use of indazole derivatives for the treatment of neuropathic pain |
| 07/26/2006 | CN1809355A Combinations comprising paroxetine and 2-(S)-(4-fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoro-2-methyl-phenyl)-ethyl]-methyl amide for treatment of depression and/or a |
| 07/26/2006 | CN1809350A Aboxadol for treating depression and other affective disorders |
| 07/26/2006 | CN1809346A Preparation of pyrrolidine-1,2-dicarboxanilide derivatives for use as factor XA and VIIA inhibiting antithrombotic agents, comprises reacting pyrrolidine-2-carboxylic acid with phenyl isocyanate then |
| 07/26/2006 | CN1808106A Method for screening acetylcholine esterase inhibitor by nuclear magnetic resonance |
| 07/26/2006 | CN1807622A Gene coding alpha-conch toxin peptide and its uses |
| 07/26/2006 | CN1807419A 1,2,4-triazole [4,3-alpha] chinoline -1-one derivative as antiepileptics medicine and its pharmaceutical salts |
| 07/26/2006 | CN1807393A Apoptosis inhibitor |
| 07/26/2006 | CN1806838A Chinese medicinal liquor |
| 07/26/2006 | CN1806808A Breviscapine orally disintegrating tablet and preparation method thereof |
| 07/26/2006 | CN1806807A Gastrodine and its derivative orally quick-acting tablet including orally disintegrating tablet and dispersible tablet and preparation method thereof |
| 07/26/2006 | CN1806806A Leponex dispersible tablet and preparation method thereof |
| 07/26/2006 | CN1806805A Leponex orally disintegrating tablet and preparation method thereof |
| 07/26/2006 | CN1806803A Perphenazine orally disintegrating tablet and preparation method thereof |
| 07/26/2006 | CN1806800A Pharmaceutical composition making pregabalin as active ingredient, its preparation method and uses |
| 07/26/2006 | CN1806696A Detoxifying, sunstroke preventing, sobering up health-care drink |
| 07/26/2006 | CN1266151C Naphthyridine derivatives |
| 07/26/2006 | CN1266129C New compounds having activity of lowing blood fat and cholesterol, their preparation method and pharmaceutical compositions containing them |
| 07/26/2006 | CN1266126C Phenethanolamine derivatives for treatment of respiratory diseases |
| 07/26/2006 | CN1266118C Novel delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides |
| 07/26/2006 | CN1265834C Chinese medicine against drug dependence |
| 07/26/2006 | CN1265814C Tanacetum parthenium extract |
| 07/26/2006 | CN1265794C Pharmaceutical composition for treating somatization disorder and its preparation process |
| 07/25/2006 | US7081513 Peptides having Chemotaxis Inhibitory Protein from Staphylococcus aureus (CHIPS) activity for diagnosis, prophylaxis and treatment of inflammation and HIV |
| 07/25/2006 | US7081476 Tocopherol enriched compositions for reducing IL6 levels |
| 07/25/2006 | US7081474 Drugs to improve synaptic transmission |
| 07/25/2006 | US7081471 (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor |
| 07/25/2006 | US7081470 Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
| 07/25/2006 | US7081468 Angiogenesis inhibitors; antitumor agents; skin disorders; antiarthritic agents |
| 07/25/2006 | US7081463 Hydroxy alkyl substituted 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1receptor mediated disorders |
| 07/25/2006 | US7081462 Imidazo-substituted compounds as p38 kinase inhibitors |
| 07/25/2006 | US7081460 Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders |
| 07/25/2006 | US7081459 1-substituted pyridine-2-ones or 2-substituted pyridazin-3-ones; anticarcinogenic agents for breast and prostate cancer; contraceptives; endometriosis, benign prostatic hypertophy |
| 07/25/2006 | US7081458 Small molecule, non-peptide antagonists; antidiabetic agents; obesity; {5-[1-4-Methoxy-2,3-dimethyl-phenyl)-ethyl]-(1S,4S)-2,5-diaza-bicyclo[2.2.1]hept-2-yl}-(4-trifluoromethyl-phenyl)-methanone |
| 07/25/2006 | US7081455 sleep disorders associated with 5-HT2A serotonin receptor modulation; antagonists or agonists |
| 07/25/2006 | US7081345 For use in diagnostic, prognostic, prophylactic or therapeutic formulation |
| 07/25/2006 | US7081252 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
| 07/25/2006 | US7081251 Administering as a transdermal patch comprising oxybutynin to provide a plasma area under the curve (AUC) ratio of oxybutynin to an oxybutynin metabolite of from about 0.5:1 to about 5:1 with a peak oxybutynin metabolite plasma concentration of less than about 8 ng/ml |
| 07/25/2006 | US7081250 Administering as a transdermal patch comprising oxybutynin to provide a plasma area under the curve (AUC) ratio of oxybutynin to an oxybutynin metabolite of from about 0.5:1 to about 5:1 with a peak oxybutynin metabolite plasma concentration of less than about 8 ng/ml |
| 07/25/2006 | US7081249 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
| 07/25/2006 | US7081239 Administering formulation comprising peptide YY or antagonists of receptors for peptide YY for manipulating the rate of upper gastrointestinal transit of a substance in a mammal having an intrinsic cholinergic afferent neural pathway |
| 07/25/2006 | CA2395869C 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives |
| 07/25/2006 | CA2369095C Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders |
| 07/25/2006 | CA2263328C Use of .gamma.-hydroxybutyric acid amides in the treatment of drug addiction and in particular of alcoholism |
| 07/25/2006 | CA2259218C Tetrahydrobenzindole compound |
| 07/25/2006 | CA2186245C Glucosidic derivatives of n-acyl alkylamines exerting neuroprotective, neurotrophic and anti-inflammatory action, useful in acute and chronic disorders of the central nervous system connected with excitotoxicity |
| 07/25/2006 | CA2182812C Pharmaceutical composition for systemic transdermal administration containing the active agent morphine-6-glucuronide |
| 07/25/2006 | CA2159603C Quinolines as type iv phosphodiesterase inhibitors |
| 07/20/2006 | WO2006076597A1 Bicyclic heterocycles as cannabinoid receptor modulators |
| 07/20/2006 | WO2006076560A1 Polymorphs of memantine hydrochloride |
| 07/20/2006 | WO2006076317A2 Aminophenyl derivatives as selective androgen receptor modulators |
| 07/20/2006 | WO2006076284A2 AMINO-IMIDAZOLONES FOR THE INHIBITION OF ß-SECRETASE |
| 07/20/2006 | WO2006075808A1 Pharmaceutical composition comprising a p25/cdk5 inhibitor for preventing or treating a neurodegenerative disease |
| 07/20/2006 | WO2006075642A1 Hypoxia response enhancing agent |
| 07/20/2006 | WO2006075619A1 2-(cyclic aminocarbonyl)indoline derivative and medicinal composition containing the same |
| 07/20/2006 | WO2006075226A1 11c-labeled benzyl-lactam compounds and their use as imaging agents |
| 07/20/2006 | WO2006075152A1 4- (1h-indol-3-yl) -pyrimidin-2-ylamine derivates and their use in therapy |
| 07/20/2006 | WO2006075011A2 Glycine reuptake inhibitors for treating drug and alcohol dependence |
| 07/20/2006 | WO2006075004A2 3, 8 - substituted 8-aza-bicyclo[3.2.1] octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 07/20/2006 | WO2006074991A1 Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels |
| 07/20/2006 | WO2006074940A2 Macrocyclic compounds and compositions useful as bace inhibitors |
| 07/20/2006 | WO2006074897A1 Cinnamate salts of a beta-2 adrenergic agonist |
| 07/20/2006 | WO2006074884A1 Thiazole-4-carboxamide derivatives as mglur5 antagonists |
| 07/20/2006 | WO2006060762A3 Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| 07/20/2006 | WO2006054057A3 New use for cannabinoid |
| 07/20/2006 | WO2006047756A3 Substituted tetracycline compounds |